Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 1;4(6):e384–e387. doi: 10.1016/S2665-9913(22)00069-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Elsevier Ltd. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Longitudinal humoral response to COVID-19 vaccination in healthy controls and patients with IMID

Humoral response represented by the spike IgG titres (A), the proportion of patients achieving an adequate spike IgG response as defined by greater than or equal to 5000 RU/mL (B), percentage neutralising capacity (C), and proportion of patients achieving an adequate neutralising capacity as defined by greater than or equal to 35% (D). (E) Proportion of patients achieving an adequate spike IgG response, by immunomodulatory use, as defined by spike IgG titres greater than or equal to 5000 RU/ml. The 4-week timepoint is defined at 4 weeks after the first dose of Janssen Ad26.COV2.S (Johnson & Johnson) and BNT162b2 (Pfizer–BioNTech) and 5 weeks after the first dose of mRNA-1273 (Moderna). IMID=immune-mediated inflammatory disease. RU=relative units.